Drug Trial Radar · NCT01478607
A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients
Last checked: Nov 20, 2026Latest source record: Oct 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
468
Actual
Start
Nov 2011
Primary completion
Feb 2014
Study completion Feb 2014
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Nov 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the safety of repeated applications of QUTENZA in reducing pain intensity in subjects who have peripheral neuropathic pain due to diabetes.
Conditions
- Painful Diabetic Peripheral Neuropathy (PDPN)
Interventions
QUTENZADrug
A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in health related quality of life (HRQOL) total score as assessed by the disease specific Norfolk scaleTime frame: Baseline till endpoint (discontinuation or End of Study visit) (up to 64 weeks)
Locations
64 sites in 11 countries. Site status is shown where the registry gives one.
Site: 601
Bonheiden, Belgium
Site: 903
Beroun, Czechia
Site: 910
Brno, Czechia
Site: 908
Choceň, Czechia
Site: 911
Litoměřice, Czechia
Site: 906
Ostrava, Czechia
Site: 904
Polička, Czechia
Site: 901
Prague, Czechia
Site: 902
Přerov, Czechia
Site: 909
Rychnov nad Kněžnou, Czechia
Site: 207
Bron, France
Site: 202
Paris, France
Site: 201
Pierre-Bénite, France
Site: 206
Toulouse, France
Site: 508
Chiemsee, Germany
Site: 509
Cologne, Germany
Site: 502
Dresden, Germany
Site: 501
Falkensee, Germany
Site: 514
Frankfurt, Germany
Site: 507
Hamburg, Germany
Site: 505
Leipzig, Germany
Site: 506
Münster, Germany
Site: 512
Wangen, Germany
Site: 404
Milan, Italy
Site: 401
Roma, Italy
Site: 651
Utrecht, Netherlands
Site: 965
Bialystok, Poland
Site: 961
Bydgoszcz, Poland
Site: 957
Elblag, Poland
Site: 958
Gdynia, Poland
Site: 954
Katowice, Poland
Site: 964
Krakow, Poland
Site: 951
Lodz, Poland
Site: 966
Lubin, Poland
Site: 953
Poznan, Poland
Site: 959
Torun, Poland
Site: 960
Warsaw, Poland
Site: 714
Kemerovo, Russia
Site: 703
Saint Petersburg, Russia
Site: 716
Saint Petersburg, Russia
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.